OMT-28_24mg_cap clinical trials

A Phase 2a Safety, Tolerability, and Pharmacodynamic Study of OMT-28 in PMD patients with myopathy and/or cardiomyopathy and inflammation (PMD-OPTION)

This study, called PMD-OPTION, is testing a new medicine, OMT-28, for adults with Primary Mitochondrial Disease (PMD) who have muscle or heart problems and inflammation. We want to see if the medicine is safe, how the body handles it, and if it can reduce a specific marker in the blood.